Anti-EGFR Agents: Current Status, Forecasts and Future Directions

Overview

Journal Target Oncol

Specialty Oncology

Date 2016 Aug 13

PMID 27515815

Citations 5

Authors

Radoslaw Kwapiszewski

Sebastian D Pawlak

Karolina Adamkiewicz

Affiliations

Soon will be listed here.

Abstract

The epidermal growth factor receptor (EGFR) is one of the most important and attractive targets for specific anticancer therapies. It is a robust regulator of pathways involved in cancer pathogenesis and progression. Thus far, clinical trials have demonstrated the benefits of monoclonal antibodies and synthetic tyrosine kinase inhibitors in targeting this receptor; however, novel strategies are still being developed. This article reviews the current state of efforts in targeting the EGFR in cancer therapy. Following a brief characterization of EGFR, we will present a complete list of anti-EGFR agents that are already approved, and available in clinical practice. Aside from the indications, we will present the sales forecasts and expiry dates of product patents for the selected agents. Finally, we discuss the novel anti-EGFR strategies that are currently in preclinical development.

Citing Articles

Advancements in understanding cardiotoxicity of EGFR- TKIs in non-small cell lung cancer treatment and beyond.

Li X, Lin Y, Lin S, Huang J, Ruan Z Front Pharmacol. 2024; 15:1404692.

PMID: 39211774 PMC: 11357958. DOI: 10.3389/fphar.2024.1404692.

EGFR TKI resistance in lung cancer cells using RNA sequencing and analytical bioinformatics tools.

Howell Jr M, Green R, Cianne J, Dayhoff 2nd G, Uversky V, Mohapatra S J Biomol Struct Dyn. 2022; 41(19):9808-9827.

PMID: 36524419 PMC: 10272293. DOI: 10.1080/07391102.2022.2153269.

Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism.

Abourehab M, Alqahtani A, Youssif B, Gouda A Molecules. 2021; 26(21).

PMID: 34771085 PMC: 8587155. DOI: 10.3390/molecules26216677.

Genetic Modification of CD8 T Cells to Express EGFR: Potential Application for Adoptive T Cell Therapies.

Lozano T, Chocarro S, Martin C, Lasarte-Cia A, Del Valle C, Gorraiz M Front Immunol. 2020; 10:2990.

PMID: 31921216 PMC: 6934060. DOI: 10.3389/fimmu.2019.02990.

Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial.

Hu X, Han X, Yang S, Li N, Wang L, Song Y Cancer Manag Res. 2019; 11:4449-4459.

PMID: 31191007 PMC: 6525002. DOI: 10.2147/CMAR.S189626.

References

Gerdes C, Nicolini V, Herter S, van Puijenbroek E, Lang S, Roemmele M . GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin Cancer Res. 2012; 19(5):1126-38. DOI: 10.1158/1078-0432.CCR-12-0989. View

Arena S, Bellosillo B, Siravegna G, Martinez A, Canadas I, Lazzari L . Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. Clin Cancer Res. 2015; 21(9):2157-66. DOI: 10.1158/1078-0432.CCR-14-2821. View

Balak M, Gong Y, Riely G, Somwar R, Li A, Zakowski M . Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. 2006; 12(21):6494-501. DOI: 10.1158/1078-0432.CCR-06-1570. View

Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y . Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014; 15(11):1236-44. DOI: 10.1016/S1470-2045(14)70381-X. View

Stewart E, Tan S, Liu G, Tsao M . Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Transl Lung Cancer Res. 2015; 4(1):67-81. PMC: 4367712. DOI: 10.3978/j.issn.2218-6751.2014.11.06. View

Lemmon M, Schlessinger J . Cell signaling by receptor tyrosine kinases. Cell. 2010; 141(7):1117-34. PMC: 2914105. DOI: 10.1016/j.cell.2010.06.011. View

Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M . Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 2012; 18(2):221-3. DOI: 10.1038/nm.2609. View

Wu D, Wang L, Sato G, West K, Harris W, Crabb J . Human epidermal growth factor (EGF) receptor sequence recognized by EGF competitive monoclonal antibodies. Evidence for the localization of the EGF-binding site. J Biol Chem. 1989; 264(29):17469-75. View

Fury M, Lipton A, Smith K, Winston C, Pfister D . A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors. Cancer Immunol Immunother. 2007; 57(2):155-63. PMC: 11030736. DOI: 10.1007/s00262-007-0357-5. View

10.

Li C, Huang S, Armstrong E, Francis D, Werner L, Sliwkowski M . Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers. Mol Cancer Ther. 2015; 14(9):2049-59. DOI: 10.1158/1535-7163.MCT-15-0155. View

11.

Alaoui-Jamali M, Morand G, da Silva S . ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics. Front Genet. 2015; 6:17. PMC: 4316710. DOI: 10.3389/fgene.2015.00017. View

12.

Kamath S, Buolamwini J . Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. Med Res Rev. 2006; 26(5):569-94. DOI: 10.1002/med.20070. View

13.

Sogabe S, Kawakita Y, Igaki S, Iwata H, Miki H, Cary D . Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors. ACS Med Chem Lett. 2014; 4(2):201-5. PMC: 4027575. DOI: 10.1021/ml300327z. View

14.

Chu C, Sada Y, Kim E . Vandetanib for the treatment of lung cancer. Expert Opin Investig Drugs. 2012; 21(8):1211-21. DOI: 10.1517/13543784.2012.694866. View

15.

Lammerts van Bueren J, Bleeker W, Brannstrom A, Von Euler A, Jansson M, Peipp M . The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proc Natl Acad Sci U S A. 2008; 105(16):6109-14. PMC: 2329681. DOI: 10.1073/pnas.0709477105. View

16.

Tian R, Li Y, Gao M . Shikonin causes cell-cycle arrest and induces apoptosis by regulating the EGFR-NF-κB signalling pathway in human epidermoid carcinoma A431 cells. Biosci Rep. 2015; 35(2). PMC: 4413019. DOI: 10.1042/BSR20150002. View

17.

Liao B, Lin C, Yang J . Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2015; 27(2):94-101. DOI: 10.1097/CCO.0000000000000164. View

18.

Azizi E, Namazi A, Haririan I, Fouladdel S, Khoshayand M, Shotorbani P . Release profile and stability evaluation of optimized chitosan/alginate nanoparticles as EGFR antisense vector. Int J Nanomedicine. 2010; 5:455-61. PMC: 2950403. DOI: 10.2147/ijn.s9551. View

19.

Hopper-Borge E, Nasto R, Ratushny V, Weiner L, Golemis E, Astsaturov I . Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets. 2009; 13(3):339-62. PMC: 2670612. DOI: 10.1517/14712590902735795. View

20.

Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Perez R . Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology. 1997; 3(1):71-81. DOI: 10.1016/s1380-2933(97)00065-1. View